OncoMatch/Clinical Trials/NCT01887340
Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma
Is NCT01887340 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Carboplatin and Etoposide for seminoma.
Treatment: Carboplatin · Etoposide · Cisplatin — The purpose of the study is to evaluate the ration of patients getting an lighten therapeutic strategy after 18F-fluoro-désoxyglucose positron emission tomography (PET-TDM) in grade I (cohort 1) or metastatic (cohort 2) seminoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Testicular Germ Cell Tumor
Disease stage
Required: Stage I, IIB, IIC, III OF GOOD PROGNOSIS
grade I; grade IIB (retroperitoneal adenopathy diameter between 2 cm and 5 cm, regardless of the LDH); grade IIC (retroperitoneal adenopathy diameter higher than 5 cm, regardless of the LDH); grade III of good prognosis (supradiaphragmatic reach with ganglionic metastasis and LDH < 2 times normal limit and/or supradiaphragmatic reach with pulmonary metastasis and LDH < 2 times normal limit) either at initial diagnosis or relapse of a grade I seminoma)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: radiotherapy
No prior treatment with radiotherapy
Cannot have received: chemotherapy
No prior treatment with chemotherapy
Lab requirements
Blood counts
PNN >= 1500, platelets >= 100 000
Kidney function
Serum creatinine <140 µmol / L (or clearance> 60 mL / min)
Liver function
ASAT (SGOT) and ALAT (SGPT) <= 1.5 x the upper limit nromale; bilirubin <= the upper limit nromale
PNN >= 1500, platelets >= 100 000, bilirubin <= the upper limit nromale; ASAT (SGOT) and ALAT (SGPT) <= 1,5 x the upper limit nromale; Serum creatinine <140 µmol / L (or clearance> 60 mL / min)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT01887340 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage I or IIB or IIC or III OF GOOD PROGNOSIS is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages